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The therapeutic response to statins has a high interindividual variability with respect to
reductions in plasma LDL-cholesterol (c-LDL) and increases in HDL cholesterol (c-HDL).
Many studies suggest that there is a relationship between the rs20455 KIF6 gene variant
(c.2155T> C, Trp719Arg) and a lower risk of cardiovascular disease in patients being
treated with statins.
Aim
The aim of this study was to investigate whether or not the c.2155T> C KIF6 gene variant
modulates the hypercholesteremic effects of treatment with simvastatin, atorvastatin, or
rosuvastatin.
Materials andmethods
This was a prospective, observational and multicenter study. Three hundred and forty-four
patients who had not undergone prior lipid-lowering treatment were recruited. Simvastatin,
atorvastatin or rosuvastatin were administered. Lipid profiles andmultiple clinical and bio-
chemical variables were assessed before and after treatment.
Results
The c.2155T> C variant of the KIF6 gene was shown to influence physiological responses
to treatment with simvastatin and atorvastatin. Patients who were homozygous for the
c.2155T> C variant (CC genotype, ArgArg) had a 7.0% smaller reduction of LDL cholesterol
levels (p = 0.015) in response to hypolipidemic treatment compared to patients with the TT
(TrpTrp) or CT (TrpArg) genotype. After pharmacological treatment with rosuvastatin,
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patients carrying the genetic variant had an increase in c-HDL that was 21.9% lower com-
pared to patients who did not carry the variant (p = 0.008).
Conclusion
Being a carrier of the c.2155T> C variant of the KIF6 gene negatively impacts patient
responses to simvastatin, atorvastatin or rosuvastatin in terms of lipid lowering effect.
Increasing the intensity of hypolipidemic therapy may be advisable for patients who are posi-
tive for the c.2155T> C variant.
Introduction
Statins are drugs that specifically inhibit 3-hydroxy-3-methyl-glutaril-CoA reductase, a rate
limiting enzyme of the pathway responsible for the synthesis of endogenous cholesterol.
Among the lipid-lowering drugs, statins are the ones most often employed to prevent athero-
sclerosis [1]. In 2015, simvastatin and atorvastin were the third and fifth most prescribed
generic drugs in Spain, respectively [2]. However, the therapeutic response to these drugs has a
high interindividual variability: the reduction in plasma LDL-cholesterol (c-LDL) resulting
from drug intake ranges from 20% to 60%. A similar variability is observed with respect to
increases in plasma HDL cholesterol (c-HDL) [3]. The impact genetic variants may have on
the effectiveness of statins is currently being investigated [4, 5, 6], with the aim of developing
personalized and cost-effective medications.
Many studies have described a relationship between the rs20455 variant of the KIF6 gene
(c.2155T> C) and differences in the response to treatment with statins. The c.2155T> C vari-
ant is a missense mutation that leads to substitution of an arginine for a tryptophan at position
719 of the KIF6 protein (NP_659464.3: p. Trp719Arg).
KIF6 is a member of the superfamily of kinesins, which are proteins that mediate the intra-
cellular transport of organelles, complex proteins, and mRNAs. Those who carry variant C are
at a higher risk of major cardiovascular events (MACE) if they do not receive hypolipidemic
treatment [7]. Paradoxically, this allele is also a predictor of better outcomes with statin-based
treatments [8, 9]. Specifically, variant C-carriers have been found to be less likely to suffer
MACE when treated with pravastatin [10, 11, 12] or atorvastatin [9, 13] than their counterparts
carrying the TT (TrpTrp) genotype. However, some reports also suggest that the association of
this variant both with MACE and with the response to statins might not exist [14, 15, 16, 17].
Importantly, this SNP is highly prevalent in Europe: 37% of Europeans are carriers [18].
In light of these facts, it is important to clarify what influence this polymorphism might
have on the efficacy of statin therapies most commonly employed in our clinical practice, such
as atorvastatin, simvastatin or rosuvastatin. Until now, most published studies have focused
only on the association between this variant and a lower risk of cardiovascular episodes. How-
ever, the effects of statins should be studied more directly. Changes in patient lipid profiles
should be measured after treatment begins. This type of study better reflects the realities of
clinical practice, in which medical decisions about changes in statin therapy are based primar-
ily on the results of lipid profiling [19].
Objective
The objective of this study was to examine how the c.2155T> C variant of the KIF6 gene influ-
ences the hypolipidemic and hypocholesterolemic responses to simvastatin, atorvastatin, and
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rosuvastatin. Responses were quantified by measuring differences in the plasma concentration
of c-LDL, Non-HDL cholesterol (c-Non-HDL), and c-HDL after treatment.
Materials andmethods
Population selection
The c.2155T> C variant of the KIF6 gene was chosen as the object of study as part of an ongo-
ing line of research into the genetic factors that influence patient responses to statins. Of par-
ticular interest were genetic variants of genes that play a role in the pharmacodynamics and
metabolism of these drugs. This was a prospective, observational, and multicenter study. Non-
medicated patients attending several Spanish Primary Health Care Units and Hospital Cardio-
vascular Risk Units with high-LDL concentration were managed as usual by their physicians.
As the design of this study was observational, statin drugs, if necessary, were prescribed in con-
ditions of normal medical practice and according solely to the patients’ physicians criteria.
The patients who were excluded from the study were those who: 1) had chronic liver disease;
2) had familial hypercholesterolemia due to mutations in their LDLR, APOB, LDLRAP1 or
PSCK9 genes; 3) suffered dysbetalipoproteinemia; 4) were receiving antidepressant, antiepilep-
tic, immunosuppressants, antiretroviral or other lipid-lowering treatments 5) were suffering
autoimmune diseases; 6) had discontinued treatment or were suspected of not adhering to pre-
scriptions, which was verified during the follow-up visit through the interview and the medical
criteria 7) had statin intolerance, which is defined as the inability to tolerate a dose of statin
required to reduce MACE sufficiently from their baseline risk and could result from different
statin related side effects including: muscle symptoms, headache, sleep disorders, dyspepsia,
nausea, rash, alopecia, erectile dysfunction, gynecomastia, and/or arthritis [20] 8) had hypo-
thyroidism; 9) were consuming 6 or more drugs (polymedication); 10) were already participat-
ing in a clinical trial.
Procedures and interventions
Data collection. Patient demographic and clinical information were collected during ini-
tial consultations. No treatments were administered during this consultation; however, lipid
metabolism was evaluated. This evaluation included measurements of triglycerides, total cho-
lesterol, c-Non-HDL, c-HDL, and c-LDL. The Friedewald formula was used when triglyceride
concentrations did not exceed 2.3 mmoL/L. An identical evaluation of lipid metabolism was
made during the final consultations, which occurred approximately 3 months after treatment
was initiated.
Genetic analysis. DNA extraction from blood samples was performed with the Maxwell
16 Blood DNA Purification Kit (catalog# AS1010) and the Maxwell 16 System Kit (catalo-
g#AS1010) (Promega, Madison, USA). Real-time polymerase chain reaction (RT-PCR) was
used to detect the c.2155T> C variant of the KIF6 gene and also the 521T> C variant of the
SLCO1B1 gene. The amplification was performed using all-specific Applied Biosystems Taq-
man probes labelled with fluorochrome in a 7500 Real Time PCR System thermocycler
(Applied Biosystems, Foster City, CA, USA).
Statistical analysis. The following independent control variables were analyzed: age, sex,
diabetes, hypertension, diastolic blood pressure, systolic blood pressure, exercise, intensity of
exercise, history of smoking, current tobacco use, history of alcohol consumption, current
alcohol consumption, body mass index, initial concentrations of c-LDL, c-Non-HDL and c-
HDL, detection of lipoprotein a, prior ischemia, family history of ischemia, and carrying the
SLCO1B1 gene variant rs4149056 [21]. Models were also fitted according to dose. Treatment
intensity was evaluated qualitatively (low, moderate, and high) according to the clinical
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practice guide of the American College of Cardiology [22]. The statistically significant control
variables (p<0.05) were selected for each model according to a simple linear regression with
the lipid concentration variations. An explanatory quantitative multiple linear regression anal-
ysis was carried out in order to discern the relationship between the differences in patient c-
LDL, c-Non-HDL and c-HDL measurements that were made during the two consultations
and detection of the c.2155T> C variant. Each statin treatment group was analyzed in this
way.
The relationship between lipid concentration variations and being a carrier of the
c.2155T> C variant was assessed using additive models. When significant differences were
observed, these were grouped according to the most appropriate model for each case (recessive
or dominant).
Statistical analyses were performed with SPSS v.17 (SPSS Inc., Chicago, IL). The level of sig-
nificance was set at p<0.05.
Ethical and confidentiality issues
Informed consent was received from study participants during their initial consultation. In
compliance with regulation #SAS/3470/2009, this study was classified by the Pharmacoepide-
miology Division of the Medicines and Health Products Agency of Spain (ref. PR169/14) and
approved by the institutional review boards of each participating center: Comité Ético de Inves-
tigación Clínica (CEIC) del Hospital Universitario de Bellvitge, CEIC Hospital universitario
Miguel Servet and CEIC Corporació Sanitària Parc Taulí.
Results
Population selection
From June 2014 to February 2017, 344 patients were recruited prospectively. However, 92 of
these were later excluded. Of the excluded, 33 had had prior hypolipidemic treatment, 3 had
statin intolerance related with muscle complications (myopathy and rhabdomyolysis), 9did not
adhere to the treatment regimen, 20 did not participate in follow-ups, 11 had been diagnosed,
through genetic testing, with familial hypercholesterolemia, 2 had hypothyroidism, 1 had an
autoimmune disease. Another thirteen were excluded for miscellaneous reasons. Consequently,
only the data from 252 of total number patients recruited for the study was analyzed.
Descriptive statistics
The clinical and demographic data of the patients is found in Table 1.
Simvastatin, atorvastatin, and rosuvastatin were prescribed to 106, 116 and 30 patients,
respectively. The genotype frequencies of this sample fulfilled the Hardy-Weinberg equilib-
rium and their distribution matched those found in the HapMap of Europe [14], (Table 2).
Figs 1, 2 and 3 show changes in serum c-LDL, c-Non-HDL and c-HDL after treatment
stratified by genotypes.
Tables 3, 4 and 5 contain the results for each drug as well as the dependent variables.
Intensity of qualitative treatment and the initial concentration of each lipid were found as
significant control variables in the case of atorvastatin, simvastatin and all patients studied
together. Concerning atorvastatin and c-Non-HDL variation, the age was also included.
Regarding rosuvastatin, prior MACE was found as significant variable for the c-LDL and c-
Non-HDL variation, and current tobacco use in the case of c-HDL variation.
Concerning patients that had been treated with simvastatin, an almost statistically signifi-
cant relationship was observed between being a carrier of the c.2155T> C variant of KIF6 and
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changes in c-LDL after treatment (p = 0.053). Treatment responses were less pronounced
among those patients who were homozygous for the mutation (CC, ArgArg) than among
those who were homozygous for the non-mutated gene (TT, TrpTrp). A similar trend was
Table 1. Patient clinical, demographic, biochemical and treatment characteristics depending on the c.2155T>C (Trp719Arg) KIF6 genotypes.
Clinical and Demographic Variables TT (TrpTrp) TC (TrpArg) CC (ArgArg) p value
Sex (% male) 48.1 51.9 57.9 0.553
Age (years) 53 (50 to 55) 54 (51 to 56) 57 (53 to 61) 0.201
Body Mass Index 26.7 (25.8 to27.7) 27.3 (26.5 to 28.0) 27.5 (26.0 to 29.0) 0.574
Tobacco Use (% yes) 37.7 21.7 19.4 0.025�
Personal history of tobacco use (% yes) 71.0 58.5 55.2 0.092
Diabetes mellitus (% yes) 18.8 13.2 24.2 0.267
Current alcohol consumption (% yes) 33.3 24.3 30 0.429
Personal history of alcohol consumption (% yes) 27.1 21.3 27.6 0.621
MACEs (% yes) 13.6 19.8 28.9 0.049�
Family history of MACEs (% yes) 38.6 38.5 35.7 0.960
Exercise (% yes) 55.4 59 65.6 0.616
Intensity of Exercise (none/low/moderate/high) % 33.3/21.6/21.6/23.5 34.6/17.3/17.3/30.9 34.8/8.7/8.7/47.8 0.417
Arterial hypertension (% yes) 27.2 30.5 36.8 0.563
Systolic Blood Pressure (SBP) (mmHg) 129.3 (125.8 to 132.8) 131.5 (128.0 to 135.0) 132.8 (127.7 to 138.0) 0.535
Diastolic Blood pressure (DBP) (mmHg) 79.8 (77.4 to 82.1) 79.0 (76.6 to 81.2) 79.2 (75.2 to 83.1) 0.891
Biochemical and Treatment Variables TT (TrpTrp) TC (TrpArg) CC (ArgArg) p value
Lipoprotein A (reference value: 0–0.3 g/L) 0.4 (0.3 to 0.5) 0.5 (0.4 to 0.6) 0.5 (0.2 to 0.7) 0.364
Serum cholesterol; initial (mmol/L) 7.3 (7.1 to 7.6) 7.1 (6.9 to 7.3) 7.2 (6.7 to 7.6) 0.562
Serum cholesterol LDL; initial (mmol/L) 5.1 (4.8 to 5.3) 4.9 (4.7 to 5.1) 4.9 (4.5 to 5.3) 0.627
Serum cholesterol no HDL; initial (mmol/L) 5.8 (5.6 to 6.0) 5.7 (5.5 to 5.9) 5.6 (5.2 to 6.0) 0.650
Serum triglycerides; initial (mmol/L) 1.9 (1.6 to 2.17) 2.1 (1.8 to 2.4) 1.7 (1.4 to 2.1) 0.343
Treatment with atorvastatin (%) 38.3 51.1 42.1 0.338
Treatment with simvastatin (%) 50.6 37.4 42.1
Treatment with rosuvastatin (%) 11.1 11.5 15.8
Intensity of Treatment (low/medium/high) % (12.3/63/24.7) (11.5/59.5/29) (10.5/44.7/44.7) 0.271
Continuous variables are expressed as averages and as 95% confidence intervals (CI95%). Categorical variables are expressed in percentages.
� indicates statistical significance.
https://doi.org/10.1371/journal.pone.0205430.t001
Table 2. Genotype distribution of the genetic variants investigated, expressed in percentages.
c.2155T>C (Trp719Arg) gene KIF6 Genotype distribution (%) p
HapMAP TT (37.2) CT (51.3) CC (11.5)
Simvastatin+Atorvastatin+Rosuvastatin TT (32.4) CT (52.4) CC (15.2) 0.37
n = 81 n = 131 n = 38
Simvastatin TT (38.7) CT (46.2) CC (15.1) 0.56
n = 41 n = 49 n = 16
Atorvastatin TT (28.4) CT (57.7) CC (13.7) 0.18
n = 31 n = 67 n = 16
Rosuvastatin TT (30.0) CT (50.0) CC (20.0) 0.38
n = 9 n = 15 n = 6
p: probability of statistical significance as calculated using the Chi squared test.
https://doi.org/10.1371/journal.pone.0205430.t002
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observed with patients who had been treated with atorvastatin. In this case, there was a statisti-
cally significant relationship between the c.2155T> C variant of KIF6 and the c-Non-HDL var-
iation after treatment (p = 0.012). There was also a clear tendency for the presence or absence
Fig 1. Changes in serum c-LDL after treatment stratified by genotypes. TT = homozygous TrpTrp; TC = heterozygous TrpArg; CC = homozygous ArgArg.
https://doi.org/10.1371/journal.pone.0205430.g001
Fig 2. Changes in serum c-Non-HDL after treatment stratified by genotypes. TT = homozygous TrpTrp; TC = heterozygous TrpArg; CC = homozygous ArgArg.
https://doi.org/10.1371/journal.pone.0205430.g002
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of the variant to be associated with c-LDL variation after treatment (p = 0.06). However, an
association between the c.2155T> C variant and c-LDL and c-Non-HDL variation after treat-
ment was not observed in the group of patients treated with rosuvastatin (p = 0.353 and
p = 0.454, respectively)
Fig 3. Changes in serum c-HDL after treatment stratified by genotypes. TT = homozygous TrpTrp; TC = heterozygous TrpArg; CC = homozygous ArgArg.
https://doi.org/10.1371/journal.pone.0205430.g003
Table 3. Multiple regression analysis that correlates the effect of the variant KIF6 on the LDL cholesterol concentration adjusted by statistically significant
covariates.
Changes in Serum LDL cholesterol concentration after treatment; (%)
Treatment Model Variables B + CI (95%) P
Simvastatin+Atorvastatin+Rosuvastatin Additive Genotypes: TT, TC, and CC 2.8 (-0.2 to 5.9) 0.070
Intensity of qualitative treatment -4.7 (-8.1 to -1.3) 0.008�
Initial concentration of c-LDL -2.4 (-4.3 to -0.6) 0.006�
Simvastatin+ Atorvastatin Additive Genotypes: TT, TC, and CC 4.0 (1.0 to 6.8) 0.010�
Intensity of qualitative treatment -6.0 (-9.2 to -2.6) 4.1x10-4�
Initial concentration of c-LDL -2.4 (-4.2 to -0.6) 0.008�
Recessive KIF6 (CC compared to T) 7.0 (1.3 to 12.6) 0.015�
Intensity of qualitative treatment -6.0 (-9.2 to -2.6) 4.1x10-4�
Initial concentration of c-LDL -2.4 (-4.2 to -0.6) 0.008�
Simvastatin Additive Genotypes: TT, TC, and CC 3.8 (-0.04 to 7.7) 0.053
Intensity of qualitative treatment -6.0 (-11.8 to -0.03) 0.039�
Atorvastatin Additive Genotypes: TT, TC, and CC 4.4 (-0.2 to 9.1) 0.064
Intensity of qualitative treatment -6.6 (-11.7 to -1.5) 0.011�
Initial concentration of c-LDL -2.9 (-5.3 a -0.5) 0.016�
Rosuvastatin Additive Genotypes: TT, TC, and CC -7.0 (-20.2 a 6.0) 0.275
Prior MACE -24.1 (-4.,7 to -2.5) 0.031�
B+CI (95%) = coefficient B + a 95% confidence interval
� indicates statistical significance.
https://doi.org/10.1371/journal.pone.0205430.t003
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Table 4. Multiple regression analysis that correlates the effect of the variant KIF6 on the Non-HDL cholesterol concentration adjusted by statistically significant
covariates.
Changes in Serum Non-HDL Cholesterol concentration after treatment; (%)
Treatment Model Variables B + CI (95%) P
Simvastatin+Atorvastatin+Rosuvastatin Additive Genotypes: TT, TC, and CC 0.8 (-1.7 to 3.4) 0.535
Intensity of qualitative treatment -4.4 (-7.2 to -1.5) 0.003�
Initial concentration of c-Non-HDL -2.6 (-4.0 to -1.2) 2.6x10-4�
Simvastatin+ Atorvastatin Additive Genotypes: TT, TC, and CC 1.7 (-0.9 to 4.4) 0.200
Intensity of qualitative treatment -5.3 (-8.2 to 2.3) 4.0x10-4�
Initial concentration of c-LDL -2.6 (-4.0 to -1.2) 2.2x10-4�
Recessive KIF6 (CC compared to T) 5.1 (0.1 to 10.1) 0.045�
Intensity of qualitative treatment -5.4 (-8.2 to -2.5) 2.8x10-4�
Initial concentration of c-LDL -2.6 (-4.0 to -1.2) 2.6x10-4�
Simvastatin Additive Genotypes: TT, TC, and CC 1.2 (-2.2 to 4.7) 0.504
Initial concentration of c-Non-HDL -3.4 (-5.4 to -1.3) 0.001�
Atorvastatin Additive Genotypes: TT, TC, and CC 3.6 (-0.4 to 7.6) 0.070
Intensity of qualitative treatment -6.2 (-10.6 to -1.8) 0.006�
Initial concentration of c-Non-HDL -2.8 (-4.7 to -1) 0.004�
Age -0.3 (-0.5 to 0.1) 0.001�
Recessive KIF6 (CC compared to T) 9.03 (2.1 to 16.5) 0.012�
Intensity of qualitative treatment -6.8 (-11.1 to -2.4) 0.003�
Initial concentration of c-Non-HDL -2.8 (-4.7 to -1.0) 0.003�
Age 0.35 (0.15 to 0.54) 0.001�
Rosuvastatin Additive Genotypes: TT, TC, and CC -3.4 (-12.9 to 6.0) 0.463
Prior MACE -15.4 (-33-3 to 2.5) 0.089
B+CI (95%) = coefficient B + a 95% confidence interval
� indicates statistical significance.
https://doi.org/10.1371/journal.pone.0205430.t004
Table 5. Multiple regression analysis that correlates the effect of the variant KIF6 on the HDL cholesterol concentration adjusted by statistically significant
covariates.
Change in Serum HDL Cholesterol concentration after treatment; (%)
Treatment Model Variables B + CI (95%) P
Simvastatin+Atorvastatin+Rosuvastatin Additive Genotypes: TT, TC, and CC 0.3 (-3.8 to 4.6) 0.860
Initial concentration of c-HDL -26.6 (-33.4 to -19.8) 3.4x10-13�
Simvastatin+ Atorvastatin Additive Genotypes: TT, TC, and CC 1.0 (-3.5 to 5.6) 0.661
Initial concentration of c-HDL -28.7 (-36.1 to -21.3) 7.1x10-13�
Simvastatin Additive Genotypes: TT, TC, and CC 1.4 (-4.8 to7.7) 0.648
Initial concentration of c-HDL -31.9 (-42.2 to -21.6) 1.39x10-8�
Atorvastatin Additive Genotypes: TT, TC, and CC 0.6 (-6.3 to 7.5) 0.857
Initial concentration of c-HDL -25.4 (-36.4 to -14.4) 1.18x10-5�
Rosuvastatin Additive Genotypes: TT, TC, and CC -11.3 (-21.5 to -1.2) 0.030�
Current tobacco use -36.3 (-60.1 a -12.5) 0.004�
Dominant KIF6 (C compared to TT) -21.9 (-37.6 to -6.2) 0.008�
Current tobacco use -41.9 (-65.7 to 18.0) 0.001�
B+CI (95%) = coefficient B + a 95% confidence interval
� indicates statistical significance.
https://doi.org/10.1371/journal.pone.0205430.t005
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When all 252 recruited patients were included in the statistical analyses and the control var-
iables were adjusted for, a clear tendency for the c.2155T> C variant and the reduction in
plasma c-LDL after treatment was found. (Additive model: p = 0.07; B + IC95% = 2.8 (-0.2 to
5.9)). When only taking into account patients who underwent treatment with simvastatin and
atorvastatin, this relationship was even more pronounced, and a statistically significant rela-
tionship was found: (additive model: p = 0.010; B + IC95% = 4 (1 to 6.8); recessive model:
p = 0.015; B + IC95% = 7 (1.3 to 12.6)).
There was also a statistically significant relationship between being a carrier of the variant
c.2155T> C and a weaker response to rosuvastatin in comparison to non-carriers, with higher
levels of c-HDL being observed after treatment (p = 0.03). However, no statistically significant
relation was found between the variant and c-HDL level changes in the simvastatin and atorva-
statin treatment groups (p = 0.648 and p = 0.857, respectively).
Based on these results, we can conclude that being a carrier of the c.2155T> C variant of
the KIF6 gene negatively impacts patient responses to statin treatments. A less pronounced
decrease in c-LDL in the case of simvastatin and atorvastatin and less pronounced increase in
c-HDL in the case of rosuvastatin are observed with respect to non-carriers.
Discussion
Statins are highly effective prophylactics against arteriosclerosis. Nevertheless, a high propor-
tion of patients consuming statins develop some type of cardiovascular disease. These out-
comes suggest that genetic factors may influence patient responses to treatment with statins
[23]. Numerous genes, such as SLCO1B1, CETP, ABCA, HMGCR, and CYP3A4 are currently
being investigated [24, 25] as possible factors affecting statin therapy outcomes. Of these, there
has been a particular focus on KIF6 gene and its variant c.2155T> C (Trp719Arg).
A member of the kinesin superfamily, the KIF6 gene encodes the protein KIF6. Kinesins
are proteins which mediate the intracellular transport of organelles, complex proteins and
mRNAs. This gene is ubiquitously expressed in coronary arteries and other vascular tissue
[26].
The effects of the c.2155T> C variant of KIF6 on the ability of statins to reduce the risk of
cardiovascular events has been documented, but the results are contradictory. Several studies
carried out by Iakouvova et al. [10, 11, 12, 13] concluded that patients that are carriers for the
variant (TC (TrpArg) + CC (ArgArg)) are less likely, compared to non-carriers, to suffer from
coronary heart disease when treated with pravastatin or atorvastatin. Meanwhile, a meta-anal-
ysis by Shiffman et al. [27] concluded that the variant affected responses to pravastatin treat-
ment. Nevertheless, these conclusions are based on data from a single research group and
therefore should be confirmed in other studies carried out independently by other groups.
Importantly, this association was not confirmed in other studies of simvastatin [28], rosu-
vastatin [29] and atorvastatin therapies [30].
In addition, others, such as Chen S. et al [31] have recently observed that patients undergo-
ing statin therapy were at significantly reduced risk for MACE in the case of all three
Trp719Arg polymorphisms. Furthermore, subjects carrying (TC) TrpArg or CC+CT (ArgArg
+TrpArg) suffered from a greater incidence of MACE when being treated with statins than TT
(TrpTrp).
As far as we know, our study is the first attempt to study the relationship between the KIF6
gene variant and the effects of statins on changes on lipid profiles using a prospective and
observational design. In addition, the analyses of these effects have been adjusted against con-
trol variables. Importantly, normal clinical procedures were reproduced: medical decisions
about therapeutic treatments were based primarily on changes in patient lipid profiles.
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According to our results, patients homozygous for variant C did not respond as well to
treatment with simvastatin and atorvastatin as did the patients who were homozygous or het-
erozygous for variant T. The same tendency was observed with rosuvastatin when measuring
increases in c-HDL levels. Considering these results, it should be noted that while Rosticci et al
[32], did not observe a relationship between the KIF6 variant and statin therapy efficacy, this
group did observe a relationship between the variant and c-HDL levels.
However, this relationship was not observed for rosuvastatin when measuring changes in c-
LDL and c-Non-HDL. This discrepancy could be explained by the fact that there were a low
number of rosuvastatin cases included in the study. Rosuvastatin is usually prescribed to high
risk populations when other statins have already been found to be insufficient. Therefore,
there were fewer of rosuvastatin cases because this prospective and observational study only
included individuals who had not undergone prior hypocholesterolemic treatment.
In a study carried out by Angelini et al. [33] it was shown that there was no relationship
between the KIF6 variant and the effects of statins on patient lipid profiles. Although an
observed trend says that subjects carrying CC (ArgArg) do not respond as well to treatment as
TT (TrpTrp) and TC (TrpArg) subjects. However, in contrast to ours, the study of Angelini
et al. was retrospective in nature, rather than prospective. In addition, the Angelini et al. study
did not adjust for dose intensity or type of statin.
Moreover, the dependent variable was qualitative: the sole criteria it depended on was
whether or not a clinical target of c-LDL� 3.4 (130 mg / dL) mmol / L was reached or not
[34].
Importantly, our results could be consistent with the latest information from the literature.
We found that there was a statistically significant correlation between being a sufferer of
MACE and being a carrier of c.2155T> C variant of KIF6 when taking into consideration all
patients prior to treatment with statins (p = 0.049). This outcome is consistent with the current
literature [35, 36, 37].
In addition, we have demonstrated that, while, c-LDL levels are reduced in all the three
genotypes in response to treatment with simvastatin and atorvastatin, c-LDL levels are reduced
to a lesser degree in the case of the variant.
Moreover, there is a general consensus that carriers benefit more from statin therapy in
terms of a lower risk of suffering from MACE. However, the reason for this relationship may
not lie in the fact that c-LDL levels decrease to a greater extent in non-carriers than in carriers.
The mechanism through which KIF6 influences statin therapy outcomes is not well under-
stood. However, our study is an important step to clarifying the relationship between the
c.2155T> C variant of KIF6 and responses to statin treatment. If our results can be confirmed, we
could hypothesize that the carriers undergoing statin treatment suffer less from MACEs due to
the pleiotropic effects of these drugs rather than a reduction in c-LDL. This hypothesis is consis-
tent with the theory posited by Iakoubova et al. [13]. In the PROVE IT-TIMI 22 study, no statisti-
cally significant relationship was found between the variant and a reduction of c-LDL levels in
response to atorvastatin or pravastatin, however, this group found that carriers benefited signifi-
cantly more from intensive statin therapy than non-carriers and hypothesized that the mechanism
could be the early plaque-stabilizing effect of the intensive treatment regimen, a pleiotropic effect
that has been proposed to explain the early benefit from statin therapy that appears not to be due
to LDL [38, 39]. However, functional studies of the KIF6 gene will be required to a better under-
stand of the mechanism between c.2155T> C variant and statin treatment.
A key outcome of our study is that we have demonstrated that carriers of variant C have a
7% smaller decrease in c-LDL or c-Non-HDL levels in response to simvastatin or atorvastatin.
The fact that the less common variant C is associated with a weaker response to treatment is
especially relevant. If this relationship were to be confirmed, patients carrying variant C could
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be considered candidates for intensive treatment with stronger statins or complementary ther-
apies. Complementary therapies include the drug Ezetimibe, or dietary supplements, such as
omega-3.
Conclusions
The c.2155T> C variant of the KIF6 gene influences patient responses to treatment with sim-
vastatin and atorvastatin. Patients homozygous for the variant (CC, ArgArg) had a smaller
decrease in the c-LDL and c-Non-HDL. Therefore, these patients did not respond as well to
hypolipidemic therapies as patients who were homozygous TT (TrpTrp) or heterozygous TC
(TrpArg). The c.2155T> C variant is associated with a less pronounced increase in c-HDL
upon rosuvastatin treatment.
These findings, if confirmed, may have an impact on the type of therapies selected for
patients carrying the genetic variant. For example, the intensity of statin therapy could be
increased, or complementary therapies, such as Ezetimibe or dietary supplements could be
employed to treat carriers.
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Funding acquisition: Cristina Ruiz-Iruela, Ariadna Padró-Miquel, Beatriz Candás-Estébanez.
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Writing – original draft: Cristina Ruiz-Iruela.
Writing – review & editing: Cristina Ruiz-Iruela, Ariadna Padró-Miquel, Beatriz Candás-
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